Johnson R D, Minneman K P
Mol Pharmacol. 1987 Mar;31(3):239-46.
Activation of alpha 1-adrenergic receptors in slices of rat brain increases inositol phosphate accumulation, increases basal cyclic AMP accumulation, and potentiates the increase in cyclic AMP caused by adenosine. We compared these three responses to determine whether they are mediated by the same receptors. The increase in inositol phosphates and the potentiation of cyclic AMP accumulation in cerebral cortex were largely blocked by chelation of extracellular calcium, whereas the increase in basal cyclic AMP was not affected. The magnitude of the increase in inositol phosphates in different brain regions correlated with the magnitude of the potentiation of cyclic AMP accumulation (r = 0.80), but neither of these correlated with the magnitude of the increase in basal cyclic AMP. Although other alkylating agents inactivated all of the alpha 1-adrenergic receptor-binding sites labeled with 125IBE 2254 in membrane preparations of cerebral cortex, chlorethylclonidine (CEC) potently and selectively inactivated only half of these sites. Pretreatment with CEC partially blocked the increase in basal cyclic AMP, but not the increase in inositol phosphates or potentiation of cyclic AMP accumulation in slices of cerebral cortex. Comparing different brain regions, there was a better correlation between the density of 125IBE 2254-binding sites not inactivated by CEC with the magnitude of the increase in inositol phosphates or potentiation of cyclic AMP accumulation than with the increase in basal cyclic AMP. Although the largest increase in inositol phosphates was observed in slices of hippocampus, there was only a small increase in basal cyclic AMP in this region, and CEC did not inactivate any 125IBE-binding sites in hippocampus. Phentolamine and WB 4101 were significantly more potent in inhibiting specific 125IBE 2254 binding in hippocampus than in cerebral cortex. After treatment of cerebral cortical membranes with CEC, however, these drugs had potencies similar to those observed in hippocampus. The results suggest that the alpha 1-adrenergic receptors mediating increases in basal cyclic AMP accumulation can be differentiated from those mediating increases in inositol phosphate accumulation and potentiating adenosine stimulated cyclic AMP accumulation by their binding properties, calcium dependency, regional distribution, and sensitivity to the alkylating agent CEC.
大鼠脑切片中α1 - 肾上腺素能受体的激活会增加肌醇磷酸的积累,增加基础环磷酸腺苷(cAMP)的积累,并增强由腺苷引起的cAMP增加。我们比较了这三种反应,以确定它们是否由相同的受体介导。大脑皮层中肌醇磷酸的增加以及cAMP积累的增强在很大程度上被细胞外钙的螯合所阻断,而基础cAMP的增加不受影响。不同脑区中肌醇磷酸增加的幅度与cAMP积累增强的幅度相关(r = 0.80),但这两者均与基础cAMP增加的幅度无关。尽管其他烷基化剂使大脑皮层膜制剂中用125I - BE 2254标记的所有α1 - 肾上腺素能受体结合位点失活,但氯乙可乐定(CEC)仅能有效且选择性地使其中一半位点失活。用CEC预处理可部分阻断基础cAMP的增加,但不能阻断大脑皮层切片中肌醇磷酸的增加或cAMP积累的增强。比较不同脑区,未被CEC失活的125I - BE 2254结合位点的密度与肌醇磷酸增加的幅度或cAMP积累增强的幅度之间的相关性,比与基础cAMP增加的幅度之间的相关性更好。尽管在海马切片中观察到肌醇磷酸的增加最大,但该区域基础cAMP的增加很小,并且CEC并未使海马中的任何125I - BE结合位点失活。酚妥拉明和WB 4101在抑制海马中特异性125I - BE 2254结合方面比在大脑皮层中更有效。然而,用CEC处理大脑皮层膜后,这些药物的效力与在海马中观察到的相似。结果表明,介导基础cAMP积累增加的α1 - 肾上腺素能受体,在结合特性、钙依赖性、区域分布以及对烷基化剂CEC的敏感性方面,可与介导肌醇磷酸积累增加和增强腺苷刺激的cAMP积累的受体区分开来。